Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.

IF 3.4 3区医学 Q3 IMMUNOLOGY

Clinical and experimental immunology Pub Date : 2024-10-16 DOI:10.1093/cei/uxae059

Olaf Neth, Nizar Mahlaoui, Charlotte Cunningham-Rundles

引用次数: 0

Abstract

Prevention and treatment of infections are primary goals of treatment of children and adults with primary immune deficiencies due to decreased antibody production. Approaches to these goals include immunoglobulin replacement therapy, vaccination, and prophylactic treatment with antimicrobials. In this review, the infectious and non-infectious complications of antibody deficiencies will be discussed along with the limited number of studies that support the effective use of the available therapies and to drive the development of new therapies. Some illustrative case studies will be presented and the outlook for additional controlled clinical trials and potential for therapies driven by the underlying disease genetics will be considered.

查看原文本刊更多论文

保护初级抗体缺乏症儿童和成人免受常见病原体、突发病原体和非感染性并发症的侵害。

预防和治疗感染是治疗因抗体生成减少而出现原发性免疫缺陷的儿童和成人的主要目标。实现这些目标的方法包括免疫球蛋白替代疗法、疫苗接种和抗菌药物预防性治疗。本综述将讨论抗体缺乏症的感染性和非感染性并发症，以及支持有效使用现有疗法和推动新疗法开发的数量有限的研究。本综述将介绍一些说明性病例研究，并探讨更多临床对照试验的前景以及由潜在疾病遗传学驱动的疗法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and experimental immunology 医学-免疫学

CiteScore

8.40

自引率

2.20%

发文量

101

审稿时长

3-8 weeks

期刊介绍： Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.